New Report Available: Medical Affairs Reputations: Renal Cell Carcinoma (US)

Opdivo's medical affairs team working overtime to engage oncologists. Is it paying off?

Opdivo's medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval for renal cell carcinoma (RCC) treatment, they've been one of the most active teams in the US market.

Is it paying off?

Find out how oncologists rate Opdivo's team, and how the teams for 7 other major RCC treatments measure up, in Medical Affairs Reputations: RCC.

You'll learn whether your team is giving oncologists the services they want, whether they're satisfied with your performance, and where you need the most improvement.

Full Report Details at
- http://www.fastmr.com/prod/1180405_medical_affairs_reputations.aspx?afid=301

Reasons to Get this Report

Answering Key Questions about Medical Affairs Teams for 8 Major RCC Brands

* Afinitor (everolimus; Novartis): Are oncologists more satisfied with Afinitor's team or Votrient's?
* Avastin (bevacizumab; Genentech): Which brand's team is tied with Avastin's for overall quality of interactions?
* Inlyta (axitinib; Pfizer): Does Inlyta's team outperform Votrient's?
* Opdivo (nivolumab; BMS): Performance scores for Opdivo's team are mostly middle of the pack, but it excels in two areas. Which two?
* Proleukin (aldesleukin; Prometheus): Proleukin's team gets high performance and satisfaction scores in most areas. How does it rank for overall quality of interactions?
* Sutent (sunitinib; Pfizer): Sutent's team is one of the leading teams in Europe. How is it doing in the US?
* Torisel (temsirolimus; Pfizer): Is Torisel's team better at responding promptly to inquiries or providing scientific and product information?
* Votrient (pazopanib; Novartis): Has Votrient's team interacted with more oncologists than Afinitor's, Avastin's, or Inlyta's in the last 6 months?

Top Takeaways

* Huge lead for #1 team: Despite average performance and satisfaction scores in several areas, its overall quality rating is more than double that of its closest competitor.
* Stiff competition downmarket: Rated for overall quality of interactions, a mere 2 points separate the 2nd place team from the 5th place team.
* Unmet need in the market: The way oncologists use medical affairs teams right now suggests high levels of unmet need in the market.
* Oncologists hungry for information: They say the most important medical affairs services involve providing information and clinical support.
* Solid performance: Scores are moderately high to high-especially in important areas. Some of the highest go to the team with the lowest overall quality rating.
* Several areas need improvement: Most teams need to improve satisfaction in 3 to 4 of the 6 services most important to oncologists.
* Satisfaction is high, but not across the board: Several teams earn high scores in most areas, but others lag.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
- Market Access Impact: Renal Cell Carcinoma (EU5)
- Market Access Impact: Renal Cell Carcinoma (US)
- Medical Affairs Reputations Non-small Cell Lung Cancer EU5
- Medical Affairs Reputations Non-small Cell Lung Cancer US